Macular Degeneration Treatment Planning Enhanced by AI

Age-related macular degeneration (AMD) affects over 11 million Americans, but treatment planning has historically relied on physician experience and generalized protocols. VisionScan's AI is changing that paradigm.

Personalized Treatment Trajectories

Our AI analyzes treatment response patterns from over 500,000 AMD patients to predict which interventions will be most effective for each individual. This precision medicine approach has improved treatment outcomes by 45% compared to standard protocols.

Monitoring Disease Progression

VisionScan's continuous monitoring capabilities track subtle changes in retinal thickness, drusen volume, and pigment alterations. The system alerts physicians to progression before symptoms appear, enabling timely treatment adjustments.

Reducing Treatment Burden

By accurately predicting which patients need frequent anti-VEGF injections versus less intensive monitoring, VisionScan helps reduce unnecessary procedures. This not only improves patient quality of life but also optimizes healthcare resource allocation.

Integration with Clinical Workflow

The technology seamlessly integrates with existing electronic health records, providing decision support without disrupting established clinical workflows. Physicians report saving an average of 12 minutes per patient consultation while improving diagnostic accuracy.

Patient Outcomes

Early adopters of VisionScan's AMD module report that 78% of patients maintain stable or improved vision at 2-year follow-up, compared to 62% with traditional monitoring approaches.